Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet …
Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver
disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on …
disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on …
Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet …
G Goodarzi, SS Tehrani, G Panahi, A Bahramzadeh… - 2023 - cabidigitallibrary.org
Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver
disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on …
disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on …
Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet …
G Goodarzi, SS Tehrani, G Panahi… - The Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver
disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on …
disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on …
Combination Therapy of Metformin and p-Coumaric Acid Mitigates Metabolic Dysfunction Associated with Obesity and Non-Alcoholic Fatty Liver Disease in High-Fat …
G Goodarzi, SS Tehrani, G Panahi… - The Journal of …, 2023 - europepmc.org
Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver
disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on …
disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on …